Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ultragenyx Pharmaceutical : to Host Conference Call for Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 08:45am EDT

NOVATO, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, February 19, 2019 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2018.

The live and replayed webcast of the call will be available through the company's website at http://ir.ultragenyx.com/events.cfm. To participate in the live call by phone, dial (855) 797-6910 (USA) or 262-912-6260 (International) and enter the passcode 6689186. The replay of the call will be available for one year.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.
Investors & MediaDanielle Keatley
415-475-6876

Source: Ultragenyx Pharmaceutical Inc.

Disclaimer

Ultragenyx Pharmaceutical Inc. published this content on 12 February 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 February 2019 13:44:04 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
04/17ULTRAGENYX PHARMACEUTICAL INC. : Regulation FD Disclosure (form 8-K)
AQ
04/16ULTRAGENYX PHARMACEUTICAL : Announces UX007 Granted Fast Track Designation and R..
AQ
04/11Ultragenyx to Present Corporate Update at Analyst and Investor Day on April 1..
GL
03/27ULTRAGENYX PHARMACEUTICAL : Announces Approval of Crysvita in Brazil for the Tre..
AQ
03/26ULTRAGENYX PHARMACEUTICAL : Announces Approval of Crysvita® (burosumab) in Brazi..
AQ
03/01ULTRAGENYX PHARMACEUTICAL INC. : Entry into a Material Definitive Agreement, Fin..
AQ
03/01ULTRAGENYX PHARMACEUTICAL : Announces Pricing of Public Offering of Common Stock
AQ
02/26ULTRAGENYX PHARMACEUTICAL : Announces Pricing of Public Offering of Common Stock
AQ
02/26ULTRAGENYX PHARMACEUTICAL : Announces Proposed Public Offering of Common Stock
AQ
02/25Ultragenyx Announces Proposed Public Offering of Common Stock
GL
More news
Financials ($)
Sales 2019 105 M
EBIT 2019 -353 M
Net income 2019 -341 M
Finance 2019 214 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 32,3x
EV / Sales 2020 15,4x
Capitalization 3 604 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 74,2 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC48.18%3 604
GILEAD SCIENCES0.64%80 255
VERTEX PHARMACEUTICALS1.48%42 991
REGENERON PHARMACEUTICALS-10.75%35 789
GENMAB5.11%10 423
SAREPTA THERAPEUTICS INC6.88%8 594